Aveo touts new hope for its thrice-failed cancer drug

Aveo Oncology ($AVEO), battered by a long series of clinical setbacks, says it has found a potential path to success with tivozanib, a cancer treatment that has failed in three trials. Looking over data from a Phase II study in colorectal cancer, the company noted that patients with low levels of the protein NRP-1 showed an improvement in progression-free survival on tivozanib compared to placebo. It should of course be noted that that same study was terminated early when Aveo revealed that tivozanib was unlikely to meet its primary endpoint, eventually leading ex-partner Astellas to abandon the program altogether. Still, the company's shares jumped nearly 40% on the latest subpopulation analysis. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.